The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of tesetaxel, an oral taxane, as second-line therapy for patients with advanced gastroesophageal cancer.
Mary Frances Mulcahy
No relevant relationships to disclose
Jackie S. Baker
Research Funding - Genta
Weijing Sun
No relevant relationships to disclose
Sun Young Rha
No relevant relationships to disclose
Hassan Danesi
Employment or Leadership Position - Genta
Loretta Itri
Employment or Leadership Position - Genta; Genta (I)
Stock Ownership - Genta (B)
Jaffer A. Ajani
Research Funding - Genta